{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:49:06Z","timestamp":1789674546806,"version":"4.0.1"},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2010,8,31]],"date-time":"2010-08-31T00:00:00Z","timestamp":1283212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[2010,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>JC virus (JCV) DNA in the cerebrospinal fluid (CSF) provides the laboratory confirmatory diagnosis of progressive multifocal leukoencephalopathy (PML) in patients whose clinical symptoms and magnetic resonance imaging findings are consistent with PML.The Laboratory of Molecular Medicine and Neuroscience (LMMN), National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), made the confirmatory laboratory diagnosis in 35 multiple sclerosis (MS) patients treated with natalizumab. Thirteen patients had 3 or more CSF samples taken from weeks to months following PML diagnosis. Seven of the 13 patients demonstrated persistence of JCV DNA in the CSF even though all patients experienced immune reconstitution inflammatory syndrome (IRIS), 11 patients had plasma exchange, and 2 had immunoabsorption. Specific anti\u2010JCV antibody was measured in plasma\/sera samples from 25 of the 35 patients. Most of the samples showed moderate to high or rising antibody levels from the time of PML diagnosis. However, plasma from 1 patient at or near the time of PML diagnosis had a titer considered seronegative and 2 other plasma samples from patients had titers considered at baseline for seropositivity. In several PML cases, viral persistence and neurological deficits have continued for several years, indicating that once initiated, JCV infection may not entirely clear, even with IRIS. Ann Neurol 2010;68:384\u2013391<\/jats:p>","DOI":"10.1002\/ana.22137","type":"journal-article","created":{"date-parts":[[2010,9,11]],"date-time":"2010-09-11T01:31:52Z","timestamp":1284168712000},"page":"384-391","source":"Crossref","is-referenced-by-count":73,"title":["JC virus persistence following progressive multifocal leukoencephalopathy in multiple sclerosis patients treated with natalizumab"],"prefix":"10.1002","volume":"68","author":[{"given":"Caroline F.","family":"Ryschkewitsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter N.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Monaco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene O.","family":"Major","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,31]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.080708.082655"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70028-4"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054693"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051847"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810316"},{"key":"e_1_2_7_7_2","unstructured":"National Institutes of Health Office of Technology Transfer Federal Register Announcement HHS Reference No. E\u2010152\u20102009\/0 July 6 2009. qPCR assay for detection of JC virus. Available at:http:\/\/www.ott.nih.gov\/Technologies\/abstractDetails.aspx?RefNo= 1977. Accessed July 28 2010."},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jviromet.2004.06.021"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.9.5346"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.82094-0"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.1.499"},{"key":"e_1_2_7_12_2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1128\/JCM.38.1.105-109.2000","article-title":"Comparison of antibody titers determined by hemagglutination inhibition (HI) and enzyme immunoassay (EIA) for JC virus and BK virus","volume":"38","author":"Hamilton R","year":"2000","journal-title":"J Clin Microbiol"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.10450"},{"key":"e_1_2_7_14_2","unstructured":"RudickR O'ConnorP PolmanC et al.Effects of natalizumab treatment on the presence of JC virus DNA in blood and urine in multiple sclerosis patients. Presented at the American Academy of Neurology (AAN) Annual Meeting Toronto April 10\u201317 2010. St. Paul MN: American Academy of Neurology 2010.S31.002."},{"key":"e_1_2_7_15_2","unstructured":"GorelikL BixlerS LernerM et al.Evaluation of the incidence of anti\u2010JCV antibodies in a cohort of natalizumab\u2010treated MS patients. Presented at the American Academy of Neurology (AAN) Annual Meeting Toronto April 10\u201317 2010. St. Paul MN: American Academy of Neurology 2010:S31.003."},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn1005-1275"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fana.22137","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fana.22137","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.22137","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T01:58:47Z","timestamp":1697421527000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.22137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,31]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["10.1002\/ana.22137"],"URL":"https:\/\/doi.org\/10.1002\/ana.22137","archive":["Portico"],"relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,31]]}}}